Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.
about
Early versus delayed erythropoietin for the anaemia of end-stage kidney diseaseEarly versus delayed erythropoietin for the anaemia of end-stage kidney diseaseHeart failure in patients with chronic kidney disease: a systematic integrative reviewShould we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study.Renal anemia treatment with ESA in hemodialysis patients in relation to early versus late referral in everyday clinical practice in Central and Eastern European countries: baseline data.Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs.Stable hemoglobin in hemodialysis patients: forest for the trees--a 12-week pilot observational studyDo two intravenous iron sucrose preparations have the same efficacy?The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: results of the MINOXIS studyCorrection of postkidney transplant anemia reduces progression of allograft nephropathy.An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.Anemia management trends in patients on peritoneal dialysis in the past 10 yearsAnaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysisIron treatment and the TREAT trial.Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of AnemiaMyocardial dysfunction occurs prior to changes in ventricular geometry in mice with chronic kidney disease (CKD)Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study.Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide.Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort studyRenal anaemia treatment in haemodialysis patients in the Central and Eastern European countries in everyday clinical practice follow-up.Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome.A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).An expert opinion on the current treatment of anemia in patients with kidney disease.Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease.Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?New treatment approaches in chronic kidney disease-associated anaemia.Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.Current and future chemical therapies for treating anaemia in chronic kidney disease.The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.Individualizing anaemia therapyAcute ischemic stroke and abnormal blood hemoglobin concentration.Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region.Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013.Should erythropoiesis-stimulating agents be used in predialysis patients?Effect of erythropoiesis-stimulating agents on hemoglobin level, fatigue and hospitalization rate in renal palliative care patients.Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement.
P2860
Q24187089-7F980D59-922C-48F5-BAB9-42AC5B840FC1Q24194838-DF0954C3-500A-4BBA-8766-93E246A7E028Q26824149-07DC7A36-B715-421E-A997-46ADA4AEE4ECQ31073395-E7A0872D-EB12-4C7A-BC6D-AE448EDDF71DQ34005174-825915DA-0486-439B-9E54-112C61A7873DQ34453236-56D6E802-CFBE-4C71-A63E-9DDB14CEFC74Q34493460-F65C1652-864E-4C93-BDF1-9346FB7C07A2Q35344826-3547EE37-B2DB-4904-B5D8-201ADE0B0779Q35692440-5A24C93B-E446-4AF0-8B2A-A7915ECDDB2FQ35715841-4F764FD9-1231-441D-96A8-6CA3DB2B6989Q35998054-721A8645-75CF-499F-8E22-AED133D58FF0Q36411715-A09AC471-7A31-4892-9611-76D845903124Q36730190-3B1C24CE-222A-4D7C-8D9E-BC930670E44FQ36745326-2FC9998A-B9F0-4031-B9C0-69B9DFA8830EQ36746039-595351B1-9972-4683-BF26-A515CFCA384CQ36773711-256C1DCF-AB9D-4A58-BF81-E9B887629474Q36801561-08EF1AC9-12C4-4E9E-8D06-E0B1F8786813Q37052058-838E940F-7BA4-4A78-AD40-BA82BA97CF53Q37157237-C6E7CE62-FE7E-46FB-990C-59BDD7DB3ECDQ37487463-54998CD3-F8BE-439E-AAC9-FF29EEA3C1ABQ37526367-6726C8AE-E58F-4761-B67C-765DF9225459Q37598414-1F074D75-AB72-4A7A-A062-E694D93A6683Q37626692-6B5ECCED-DF22-4CF0-96C3-5820DCF21EA3Q37980546-FEADD458-215E-4ECF-8555-C7D3F96862C6Q38037120-EE2EBA99-9A21-41A6-BFF8-49CB0464E9D2Q38051056-22468FAA-80D1-4C61-BFFE-3FA66AA0D8B4Q38192002-D5A8AA21-1E46-4E62-8C4E-BDEB53C637A9Q38229636-4F0AF139-997E-4B5A-9F54-6E15541310FDQ38690858-91CE1CB6-8D5F-466B-AD51-F5F050D07CA0Q38740871-214C1A09-4898-4E96-870F-BEFF54E2F42EQ38826645-D549F4AC-7DB6-4FF9-92A7-ECCF1E13A32BQ40329273-95786C2A-F21E-4686-A2FF-02925C05A247Q40408219-98AA7403-006E-4B4E-9072-D35FD8E96E99Q41012196-E3CFCEBD-1982-4CEB-B0E6-4DA3398F28ADQ41513457-562A692F-9A01-491C-86C4-D58122047042Q41835623-93AD651D-A434-4DA0-8515-F5286553BDA9Q44388327-14C0B8B2-6F85-4CDC-B83D-AA2CF14CE894Q44927431-1B82D6AA-E17D-4352-8382-B95EC08C7E9CQ44963037-444C2990-A2F5-4702-B8A1-2FD6BF7E5136Q45012876-1A6DA7FC-E7F2-4700-9EF5-AD5ED397DFFE
P2860
Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Target haemoglobin to aim for ...... Aranesp therapy (TREAT) study.
@ast
Target haemoglobin to aim for ...... Aranesp therapy (TREAT) study.
@en
Target haemoglobin to aim for ...... ar events with Aranesp therapy
@nl
type
label
Target haemoglobin to aim for ...... Aranesp therapy (TREAT) study.
@ast
Target haemoglobin to aim for ...... Aranesp therapy (TREAT) study.
@en
Target haemoglobin to aim for ...... ar events with Aranesp therapy
@nl
prefLabel
Target haemoglobin to aim for ...... Aranesp therapy (TREAT) study.
@ast
Target haemoglobin to aim for ...... Aranesp therapy (TREAT) study.
@en
Target haemoglobin to aim for ...... ar events with Aranesp therapy
@nl
P2093
P356
P1476
Target haemoglobin to aim for ...... Aranesp therapy (TREAT) study.
@en
P2093
Anaemia Working Group of European Renal Best Practice (ERBP)
Andrzej Wiecek
Angel De Francisco
Bernard Canaud
Francesco Locatelli
Iain C Macdougall
Pedro Aljama
P304
P356
10.1093/NDT/GFQ336
P407
P577
2010-06-29T00:00:00Z